An interventional study of Group with AI iCAD version 3 and Group without AI in Breast Cancer Screening, Artificial Intelligence (AI) and Breast Cancer Screening and Diagnosis, sponsored by University Hospital Olomouc. Recruiting at 1 site in Czechia. Open to female participants aged 45 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by University Hospital Olomouc · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Breast Neoplasms with a site in Czechia — 21 open to participants now, 44 under way, 31 of them phase 3. Breast Neoplasms · Czechia.
Among the 177 studies in Breast Neoplasms with a site in Czechia, this one is the 2nd largest by planned enrollment of the 161 interventional ones that give a count, is one of 14 that started in 2025, is one of 9 with no phase, reaches primary completion later than 32 of the 43 other live ones, and was the 168th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →21 of the 177 studies in Breast Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Czechia, United States, Argentina and 23 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Czechia, United States, Canada and 8 more countries
Ages 18+
Masaryk Memorial Cancer Institute · Sites in Czechia
Ages 20–55 · Women only · Healthy volunteers
Olema Oncology, Inc. · Sites in Czechia, United States, Australia and 21 more countries
Ages 18+
BioNTech SE · Sites in Czechia, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 45 Years to 69 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 49 · Phase 3 103
First in 1996; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8,000 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 500 across the 161 interventional studies, 200 across the 15 observational. Of the 131 that completed or were terminated, 98 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 177 have an industry lead sponsor. The 10 most frequent:
University Hospital Olomouc is the lead sponsor of 40 studies on the registry; 13 are open to participants now.
University Hospital Olomouc has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Breast Neoplasms with a site in Czechia that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT06312176Phase 3Merck Sharp & Dohme LLCA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | 2027-07-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 177 studies in Breast Neoplasms with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized prospective study comparing the evaluation of mammography images in a breast cancer screening programme by a single radiologist with AI support versus standard double reading by two radiologists without AI support.
In the intervention group, the first reading of the screening mammogram will be performed by one radiologist with AI support. After this AI-assisted first reading is completed and recorded for the study, a standard second reading will be carried out by another radiologist. This ensures that the legal requirement for double reading in the breast cancer screening program is maintained.
In the control group, mammograms will be evaluated according to the current standard practice - that is, independently by two radiologists without AI support.
Participants will be divided to the two groups based on a randomization scheme that determines specific days for evaluation with AI (Group 1) and without AI (Group 2). The randomization ensures equal distribution of weekdays between the two groups to minimize bias due to variability in daily workflow, diagnostic/screening ratios, or other operational factors.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
This study's planned enrollment of 8,000 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →University Hospital Olomouc is the lead sponsor of 40 studies on the registry; 13 are open to participants now.
Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Asymptomatic women aged 45-69 participating in breast cancer screening programme, reading of mammograms by one radiologist with AI support.
Diagnostic Test: Group with AI iCAD version 3
Asymptomatic women aged 45-69 participating in breast cancer screening programme, reading of mammograms by two radiologists without AI (current practice).
Diagnostic Test: Group without AI
Reading mammograms by one radiologist with AI support
Standard double reading by two radiologists without AI.
Further assessment rate
The proportion of women udergoing follow-up examinations within 0-190 days after screening mammography.
Time frame: up to 190 days after screening mammmography
Cancer Detection Rate
The number of cancers detected per 1,000 women screened.
Time frame: up to 1 year after screening mammography
Recall Rate
The proportion of women recalled for follow-up examinations withing 1-190 days after screening mammography.
Time frame: up to 190 days after screening mammography
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 35 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 35 months is close to that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Olomouc